PALO ALTO, Calif., March 17, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma.

The pre-clinical study will be conducted by Shanghai First People's Hospital, a leading teaching hospital affiliated with Shanghai Jiaotong University. Professor Zhou Xin, director of the hospital's respiratory department and chairperson of Respiratory Diseases Division of Shanghai Medical Association, will lead the study as Principal Investigator.

Dr. Wei (William) Cao, Chief Executive Officer of Cellular Biomedicine Group, Inc., commented, "Asthma places a significant burden on families and communities in China. With 300 million people worldwide and over 30 million people in China suffering from asthma without effective therapies, this disease represents a meaningful unmet medical need. We are very excited to be developing a cellular medicine solution that may have the potential to improve the quality of life for millions of people in China and globally."

About Asthma in China

Respiratory diseases account for 15% of deaths in China. China has the largest asthmatic population in the world and is one of the countries with the highest asthma mortality rate. (Source: Respirology 2013, Asian Pacific Society of Respirology) Asthma is a chronic disease of the air passages of the lungs that inflames and narrows them, with symptoms of wheezing, breathlessness, coughing and/or chest tightness. The disease can have a severe impact on quality of life and can be a life-threatening disease if not properly managed.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064

Vivian Chen
Managing Director Investor Relations, Grayling
+1 646 284-9427


Christopher Chu
Director Investor Relations, Grayling
+1 646 284-9426